Axsome Therapeutics Reports 57% Q1 Revenue Growth Amid Widening Loss
Summary
Axsome Therapeutics reported a significant 57% increase in Q1 net product revenue, reaching $191.2 million, primarily driven by strong sales of Auvelity and Sunosi. However, the company's net loss widened to $64.5 million due to increased operating expenses related to pre-launch and commercialization activities. This financial update follows the recent FDA approval for Auvelity to treat agitation associated with Alzheimer's disease, which was announced just days prior. While the widening loss is a concern, it is largely attributed to strategic investments in commercialization efforts for newly approved indications, which are expected to drive future revenue growth. Investors will now focus on the upcoming commercial launch of Auvelity for Alzheimer's disease agitation in June 2026 and topline results from the ENGAGE Phase 3 trial in the second half of the year.
At the time of this announcement, AXSM was trading at $202.26 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $10.6B. The 52-week trading range was $96.09 to $217.00. This news item was assessed with neutral market sentiment and an importance score of 7 out of 10. Source: Reuters.